RxDoctor Payments Data

Navdeep Loomba, MD

Interventional Pain Medicine · Victorville, CANPI 1770527095

Payments from drug & device makers

$5,042in general payments, 2019–2025

Across 197 payments — averaging $25.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$631
  • Collegium Pharmaceutical, Inc.$438
  • AbbVie$327
  • Valinor Pharma, LLC$294
  • Pfizer$236
  • plus $1K from 14 others

What the payments were for

  • Travel & lodging$1,14823%
  • Food & beverage$3,89577%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,042 in reported general payments places this provider in the 60th percentile of 188 interventional pain medicine providers in California.

See all interventional pain medicine providers in California

Medicare billing

Part B allowed, 2024
$449,375
Medicare patients
418
Services billed
33,235

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen6,296$136,628
MovantikNaloxegol Oxalate294$115,064
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen2,451$63,895
ZtlidoLidocaine130$50,334
Lidocaine638$43,376
OxycontinOxycodone Hcl77$40,621
Morphine Sulfate ErMorphine Sulfate1,590$35,294
Nucynta ErTapentadol Hcl20$27,104
RelistorMethylnaltrexone Bromide12$25,110
Buprenorphine118$22,088
Nurtec OdtRimegepant Sulfate14$18,466
UbrelvyUbrogepant17$16,964
Fentanyl176$15,110
LinzessLinaclotide27$14,189
Baclofen1,501$13,540

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Redhill Biopharma Inc.Movantik$125$115,064294 claims
Scilex Pharmaceuticals Inc.Ztlido$184$50,334130 claims
Collegium Pharmaceutical, Inc.Nucynta Er, Belbuca, Xtampza Er$438$42,21155 claims
AbbVieUbrelvy, Linzess$327$31,15344 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor$631$25,11012 claims
PfizerNurtec Odt$236$18,46614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 188 interventional pain medicine providers in California.

Other interventional pain medicine in Victorville

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →